Financials

  • Market Capitalization 50.01 M
  • Employee 58
  • Founded 2005
  • CEO N/A
  • Website www.atyrpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG001J2P692
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.98
Price to sales ratio
383.25

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4295
TCRT
Alaunos Therapeutics, Inc. - Common Stock
2.06 USD-0.96%-0.96%-13.08%-22.82%50.31 M USD
4300
MGX
Metagenomi Therapeutics, Inc. - Common Stock
1.35 USD+2.27%+7.14%+10.66%-6.25%50.82 M USD
4305
MCRB
Seres Therapeutics, Inc. - Common Stock
5.21 USD-7.30%-32.43%-10.48%-36.70%49.94 M USD
4307
INMB
INmune Bio Inc. - Common stock
2.00 USD+7.53%+26.58%+58.73%-6.10%53.17 M USD

Frequently asked questions about aTyr Pharma, Inc. - Common Stock

What is the aTyr Pharma, Inc. - Common Stock stock price today?

The current price of aTyr Pharma, Inc. - Common Stock (ATYR) is 0.51. Over the past 24 hours, the stock has changed by +2.00%. Follow the ATYR chart for real-time price dynamics.

What is the stock ticker of aTyr Pharma, Inc. - Common Stock?

aTyr Pharma, Inc. - Common Stock trades under the ticker ATYR. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is aTyr Pharma, Inc. - Common Stock stock going up?

ATYR has changed by -26.09% over the last week, +8.51% over the last month, and -47.42% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was aTyr Pharma, Inc. - Common Stock net income for the last quarter?

aTyr Pharma, Inc. - Common Stock reported net income of -10.79 M for the last quarter. The previous quarter showed -13.96 M, which means net income changed by +22.72%.

How many employees does aTyr Pharma, Inc. - Common Stock have?

As of the latest available data, aTyr Pharma, Inc. - Common Stock has 58 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy aTyr Pharma, Inc. - Common Stock stock?

You can buy aTyr Pharma, Inc. - Common Stock (ATYR) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in aTyr Pharma, Inc. - Common Stock stock?

Investing in aTyr Pharma, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the ATYR chart and related analysis on metatrader.com as part of your research.

aTyr Pharma, Inc. - Common Stock

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.